Intalight Celebrates CE Mark for DREAM OCT™ Platform
Intalight, a pioneering company in the field of advanced ophthalmic technologies, is thrilled to announce it has received the prestigious CE mark for its innovative DREAM OCT™ platform. This significant milestone allows Intalight to commercialize its cutting-edge imaging solution across Europe.
Understanding the DREAM OCT™ Technology
The DREAM OCT™ platform stands for Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging. This groundbreaking technology sets itself apart by delivering unparalleled OCT images that are currently unparalleled in quality on the market.
The Benefits of DREAM Imaging
With the capability to capture an ultra-wide field in a single scan, the DREAM OCT™ platform can produce 130° OCTA images, showcasing intricate details of the choroid and retina. Furthermore, the swept-source scanning technology achieves remarkable depths, allowing for comprehensive imaging of the anterior segment, extending from the cornea to the anterior part of the vitreous, all in just one scan.
Implications for ophthalmologists
Shawn Peng, Intalight's Chairman and Founder, expressed pride in achieving this milestone, highlighting how it empowers ophthalmologists in Europe with advanced tools to significantly enhance patient outcomes. The company aims to bridge the gap between cutting-edge technology and practical clinical application.
Features Driving Innovation
Equipped with a longer wavelength, the DREAM OCT™ platform provides superior penetration through opacities found in lenses and the vitreous, setting a new standard for imaging in challenging conditions.
DREAM OCT™ in the Market
Bing Li, CEO and Co-Founder of Intalight, reflected on the invaluable feedback gathered from eye care professionals, emphasizing the urgent need for rapid, accurate imaging solutions. The functionality of DREAM OCT™ supports both clinical and research applications, addressing the demand for precise and comprehensive imaging of the retina.
Research and Development Impact
Over 160 peer-reviewed papers have already reported findings using DREAM OCT™ devices, underscoring its significant contributions to the field of ophthalmology. This is a testament to Intalight's commitment to advancing ophthalmic science.
Future Opportunities and Global Reach
Joe Garibaldi, Chief Commercial Officer of Intalight, shared his excitement about expanding access to this revolutionary technology beyond Europe, expressing hopes for future FDA approval. The company focuses on building its network with elite institutions and ophthalmologists worldwide.
Collaboration with Renowned Institutions
As a clinically validated leader in ultra-wide field OCTA, Intalight collaborates extensively with premier academic and private retina practices across various continents, including North America and Asia, enhancing their research and diagnostic capabilities.
About Intalight Inc.
Founded by a dedicated team of Silicon Valley scientists and industry experts, Intalight is at the forefront of developing cutting-edge ophthalmic technologies. With operational sites in Silicon Valley, Shanghai, and Luoyang, the company's focus is on advancing the limits of optical coherence tomography as exemplified by the DREAM OCT™ platform. By integrating groundbreaking imaging depth, swift scanning capabilities, comprehensive scan ranges, and accurate multimodal imaging, this device has become essential in both clinical practices and research explorations.
Frequently Asked Questions
What is the significance of the CE mark for Intalight?
The CE mark signifies that Intalight’s DREAM OCT™ technology meets the essential requirements for health and safety standards in the European Market, enabling commercial distribution.
How does the DREAM OCT™ platform improve patient outcomes?
The platform provides high-quality imaging that assists in accurate diagnoses and treatment planning, ultimately leading to better patient care in ophthalmology.
What unique features does the DREAM OCT™ offer?
The technology offers deep imaging depth, wide scanning range, and rapid acquisition time, along with the capability to perform multimodal imaging.
How has the market responded to DREAM OCT™?
The technology has been recognized for its advanced imaging capabilities, already referenced in over 160 peer-reviewed papers, indicating its importance in the field.
What are Intalight’s future plans?
Intalight aims to enhance its global presence by securing FDA approval, thereby increasing access to the DREAM OCT™ platform across various markets.
